Taysha Gene Therapies (TSHA) Asset Writedowns and Impairment (2023 - 2024)
Taysha Gene Therapies' (TSHA) quarterly Asset Writedowns and Impairment came in at $4.8 million in Q3 2024, up 685.39% year-on-year from $616000.0 in Q4 2023, and up 977.51% quarter-over-quarter from $449000.0 in Q4 2023.
Taysha Gene Therapies (TSHA) Asset Writedowns and Impairment (2023 - 2024) Analysis & Trends
Taysha Gene Therapies has disclosed Asset Writedowns and Impairment across 2 years of filings, most recently posting $4.8 million for Q3 2024.
- Asset Writedowns and Impairment for Q3 2024 came in at $4.8 million, up 685.39% year-over-year; the trailing twelve-month figure through Dec 2025 was $4.8 million (down 18.04% YoY), and the FY2024 annual result was $4.8 million, up 354.27% from the prior year.
- Asset Writedowns and Impairment came in at $4.8 million for Q3 2024 at Taysha Gene Therapies, up from $449000.0 in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $4.8 million in Q3 2024 to a low of $449000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Taysha Gene Therapies | 2.36 Bn | 2.36 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 4.84 Mn |
| Sep 30, 2024 | 4.84 Mn |
| Dec 31, 2023 | 449,000.00 |
| Dec 31, 2023 | 449,000.00 |
| Sep 30, 2023 | 616,000.00 |
| Sep 30, 2023 | 616,000.00 |